Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ · Healthcare · Biotechnology
Madrigal Pharmaceuticals Inc is a Healthcare company with a market capitalization of $11.60B.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $-1.38 | $-4.14 | +66.7% |
| Q4 2025 | February 19, 2026 | $-2.57 | $-0.60 | -325.6% |
| Q3 2025 | November 4, 2025 | $-4.96 | $-1.99 | -149.3% |
| Q2 2025 | August 5, 2025 | $-1.90 | $-3.53 | +46.2% |
| Q1 2025 | May 1, 2025 | $-3.32 | $-3.79 | +12.4% |
| Q4 2024 | February 26, 2025 | $-2.71 | $-4.12 | +34.3% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 2,062,862 | 7.11% | 6.9 | -41.5% |
| June 30, 2026 | 3,526,539 | 12.15% | 6.2 | -6.7% |
| June 15, 2026 | 3,780,568 | 13.02% | 14.3 | -1.1% |
| May 29, 2026 | 3,823,127 | 13.17% | 14.1 | -1.9% |
| May 15, 2026 | 3,897,454 | 13.42% | 12.3 | +1.1% |
| April 30, 2026 | 3,854,441 | 17.18% | 16.5 | -4.0% |
| April 15, 2026 | 4,012,756 | 17.89% | 12.7 | +2.6% |
| March 31, 2026 | 3,909,299 | 17.43% | 9.1 | -0.5% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc's market cap?
As of August 13, 2026, Madrigal Pharmaceuticals Inc (MDGL) has a market capitalization of $11.60B.
Does Madrigal Pharmaceuticals Inc pay a dividend?
Madrigal Pharmaceuticals Inc does not currently pay a dividend.
What sector is MDGL in?
Madrigal Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Madrigal Pharmaceuticals Inc's short interest?
As of the July 15, 2026 FINRA settlement, 2,062,862 MDGL shares were sold short, or 7.11% of shares outstanding. Days to cover: 6.9. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Madrigal Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Madrigal Pharmaceuticals Inc reported revenue of $958.40M and net income of -$288.28M.
Ask your own questions about MDGL
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.